Roxadustat advantageous for improving anemia in chronic kidney disease

A new study found that Roxadustat is very effective in improving anemia with no significant adverse events in patients with chronic kidney disease. The study results were published in the journal Biomed Research International. 

Renal anemia is one of the common complications of patients with chronic kidney disease (CKD). Most of the patients on long-term dialysis have this. Roxadustat, a newly listed oral hypoxia-inducible factor-proline enhancing enzyme inhibitor (HIF-PHI) has been prescribed in some countries for the management of renal anemia. Studies in the past have shown the efficacy of roxadustat in the treatment of renal anemia in patients with chronic kidney disease (CKD). As there are various conclusions on its safety, a meta-analysis has been conducted to explore the efficacy and safety of roxadustat in the treatment of renal anemia, including the adverse events involved in each study. 

Following PRISMA guidelines, PubMed, Embase, Cochrane, and Clinical Trials were searched for randomized controlled trials (RCTs) that assess the efficacy and safety of roxadustat treatment for anemia in CKD patients. The quality of included literature was evaluated using the Cochrane Literature Quality Evaluation Scale. Fixed-effects model or random-effects model was used for data processing based on heterogeneity.